Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.

ABSTRACT:

Background

The safety and efficacy data of the different types of available vaccines is still needed. The goal of the present analysis was to evaluate the humoral response to the COVID-19 vaccines in orthotopic liver transplant (OLT) recipients.

Methods

Participants were included from February to September 2021. No prioritized vaccination roll call applied for OLT patients. Controls were otherwise healthy people. Blood samples were drawn after 15 days of the complete vaccine doses. The samples were analyzed according to the manufacturer's instructions using the Liaison XL platform from DiaSorin (DiaSorin S.p.A., Italy), and SARS-COV-2 IgG II Quant (Abbott Diagnostics, IL, USA).

Results

A total of 187 participants (133 OLT, 54 controls, median age: 60 years, 58.8% wome

SUBMITTER: Toapanta-Yanchapaxi L 

PROVIDER: S-EPMC9393170 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature